Analysis of the expression changes of IL-17+ γδ T cells and Treg cells in bone marrow mesenchymal stem cells targeted therapy for allergic rhinitis
OBJECTIVE: Bone marrow mesenchymal stem cells (BMSCs) have immunomodulatory and therapeutic effects on immune system diseases. This study intends to assess the regulatory effect of BMSC targeted therapy on the IL-17+ γδ T cells and Treg cells in allergic rhinitis (AR).
MATERIALS AND METHODS: BALB/c mice were sensitized by ovalbumin (OVA), while BMSCs were injected intravenously before sensitization and followed by an analysis of nasal symptoms, inflammation, cytokines, and immunoglobulins. BMSCs were co-cultured with peripheral blood mononuclear cells for 3 days to test Foxp3+ expression, IL-17+ γδ T and Foxp3+Treg cell ratio, and cytokines secretion.
RESULTS: After intranasal administration of BMSCs, nasal symptoms and inflammatory infiltration in mice were significantly alleviated, accompanied by reduced OVA-specific IgE in serum. BMSCs significantly inhibited the activity of T lymphocytes, increased TGF-β1 level, decreased IL-17A level, promoted Treg proliferation, and suppressed the proliferation of IL-17+ γδ T cells.
CONCLUSIONS: BMSC targeted therapy can be used to treat AR by regulating Treg cells to correct IL-17+γδ T cell immune imbalance and is expected to be an effective treatment method for AR.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
European review for medical and pharmacological sciences - 25(2021), 7 vom: 20. Apr., Seite 2858-2865 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zou, B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9006-59-1 |
|---|
| Anmerkungen: |
Date Completed 06.01.2022 Date Revised 06.01.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.26355/eurrev_202104_25539 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324320930 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324320930 | ||
| 003 | DE-627 | ||
| 005 | 20231225190054.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.26355/eurrev_202104_25539 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1081.xml |
| 035 | |a (DE-627)NLM324320930 | ||
| 035 | |a (NLM)33877651 | ||
| 035 | |a (PII)25539 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zou, B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analysis of the expression changes of IL-17+ γδ T cells and Treg cells in bone marrow mesenchymal stem cells targeted therapy for allergic rhinitis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.01.2022 | ||
| 500 | |a Date Revised 06.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: Bone marrow mesenchymal stem cells (BMSCs) have immunomodulatory and therapeutic effects on immune system diseases. This study intends to assess the regulatory effect of BMSC targeted therapy on the IL-17+ γδ T cells and Treg cells in allergic rhinitis (AR) | ||
| 520 | |a MATERIALS AND METHODS: BALB/c mice were sensitized by ovalbumin (OVA), while BMSCs were injected intravenously before sensitization and followed by an analysis of nasal symptoms, inflammation, cytokines, and immunoglobulins. BMSCs were co-cultured with peripheral blood mononuclear cells for 3 days to test Foxp3+ expression, IL-17+ γδ T and Foxp3+Treg cell ratio, and cytokines secretion | ||
| 520 | |a RESULTS: After intranasal administration of BMSCs, nasal symptoms and inflammatory infiltration in mice were significantly alleviated, accompanied by reduced OVA-specific IgE in serum. BMSCs significantly inhibited the activity of T lymphocytes, increased TGF-β1 level, decreased IL-17A level, promoted Treg proliferation, and suppressed the proliferation of IL-17+ γδ T cells | ||
| 520 | |a CONCLUSIONS: BMSC targeted therapy can be used to treat AR by regulating Treg cells to correct IL-17+γδ T cell immune imbalance and is expected to be an effective treatment method for AR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Interleukin-17 |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell, gamma-delta |2 NLM | |
| 650 | 7 | |a Ovalbumin |2 NLM | |
| 650 | 7 | |a 9006-59-1 |2 NLM | |
| 700 | 1 | |a Zhuang, R-X |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, X-Y |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European review for medical and pharmacological sciences |d 1997 |g 25(2021), 7 vom: 20. Apr., Seite 2858-2865 |w (DE-627)NLM09387944X |x 2284-0729 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2021 |g number:7 |g day:20 |g month:04 |g pages:2858-2865 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26355/eurrev_202104_25539 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2021 |e 7 |b 20 |c 04 |h 2858-2865 | ||